NL-OMON45818尚未招募2 期
SAKK 06/14. A phase I/II open label clinical trial assessing safety and efficacy of intravesical instillation of VPM1002BC in patients with recurrent non-muscle invasive bladder cancer after standard BCG therapy - VPM1002BC in recurrent non-muscle invasive bladder cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •Histologically confirmed diagnosis of recurrent NMIBC
- •Negative cytology (except for CIS)
- •Planned treatment starts 2-6 weeks after last TURB
- •One previous cycle of intravesical BCG (induction phase with at least 5 instillations) not more than 5 years ago for NMIBC
- •Recurrent high-risk NMIBC for progression
排除标准
- •Stress urinary incontinence >I°, urge urinary incontinence
- •Active concomitant malignant conditions
- •Primary or secondary immunodeficiencies
- •Positive HIV test
- •Chronic administration of immunosuppressive drugs
- •Uncontrollable urinary tract infection
研究者
相似试验
进行中（未招募）
1 期
Clinical study in patients with bladder cancerEUCTR2014-005330-58-NLSAKK (Schweizerische Arbeitsgemeinschaft für klinische Krebsforschung)39
进行中（未招募）
1 期
A phase I-IIa clinical trial, evaluating the therapeutic vaccine hVEGF26-104/RFASE in patients with advanced cancerAdvanced solid tumorsMedDRA version: 16.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2013-002663-25-NLVU University Medical Center27
进行中（未招募）
1 期
Afatinib phase II trial in urothelial cancer patients with HER2/3 mutationspatients with advanced/metastatic urothelial tract carcinoma with ERBB receptor deregulationMedDRA version: 18.1 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005427-10-ESBoehringer Ingelheim España, S.A.350
已完成
不适用
A phase I-II open label clinical trial, evaluating the efficacy and safety of administration of the therapeutic vaccine PEP-223/CoVaccine HT, to hormone treatment naive, immunocompetent subjects with T1-3, N0-1/x, M0 prostate cancer, eligible for hormone therapy.prostate cancerNL-OMON35662Pepscan Therapeutics B.V.12
进行中（未招募）
1 期
To evaluate the safety and tolerability of Cytokine cocktail therapy in healthy volunteers from healthy donorsCTRI/2020/05/025432Health Care Global HCG Cancer CentreInternational stemcell services ltd